A novel PD1-CD40 bispecific antibody YH008 induces potent anti-tumor activity in vivo by PD1 dependent activation of CD40 signaling.

被引：0
|
作者：
Liu, Baihong [1 ]
Hui, Li [2 ]
Liu, Chonghui [1 ]
Li, Zhihong [3 ]
Pan, Fangxia [1 ]
Yang, Benny [1 ]
Lin, Qingcong [2 ]
机构：
[1] Biocytogen, Beijing, Peoples R China
[2] Biocytogen, Wakefield, MA USA
[3] Eucure Beijing Biopharma Co Ltd, Wakefield, MA USA
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1852
引用
收藏
页数：2
相关论文
共 50 条
  • [1] YH008, a PD-1-CD40 bispecific antibody, inhibits tumor growth in vivo through PD-1-dependent activation of CD40 signaling.
    Liu, Baihong
    Yang, Hao
    Hui, Li
    Yang, Benny
    CANCER RESEARCH, 2022, 82 (12)
  • [2] Prediction of pharmacokinetics and receptor occupancy of a bispecific antibody against CD40 and PD-L1
    Diakonova, Alexandra
    Demin, Oleg
    Shchelokov, Dmitry
    Demin, Oleg
    CANCER RESEARCH, 2022, 82 (12)
  • [3] Design of a humanized CD40 agonist antibody with specific properties using AlphaFold2 and development of an anti-PD-L1/CD40 bispecific antibody for cancer immunotherapy
    Du, Kun
    Huang, He
    TRANSLATIONAL ONCOLOGY, 2025, 52
  • [4] In vivo efficacy and safety evaluation of anti-human PD-1 and CD40 mAbs using double humanized PD-1/CD40 mouse model
    Guo, Yanan
    CANCER RESEARCH, 2019, 79 (13)
  • [5] A bispecific anti-PD-1 and PD-L1 antibody induces PD-1 cleavage and provides enhanced anti-tumor activity
    Albu, Diana I.
    Wolf, Benjamin J.
    Qin, Yan
    Wang, Xianzhe
    Ulumben, Amy Daniel
    Su, Mei
    Li, Vivian
    Ding, Eirene
    Gonzalo, Jose Angel
    Kong, Jason
    Jadhav, Ruturaj
    Kuklin, Nelly
    Visintin, Alberto
    Gong, Bing
    Schuetz, Thomas J.
    ONCOIMMUNOLOGY, 2024, 13 (01):
  • [6] A BISPECIFIC ANTIBODY TARGETING CD40 AND EPCAM INDUCES SUPERIOR ANTI-TUMOR EFFECTS COMPARED TO THE COMBINATION OF THE MONOSPECIFIC ANTIBODIES
    Ellmark, Peter
    Hagerbrand, Karin
    Levin, Mattias
    Von Schantz, Laura
    Deronic, Adnan
    Varas, Laura
    Sall, Anna
    Barchan, Karin
    Werchau, Doreen
    Ljug, Lill
    Thageson, Mia
    Rosen, Anna
    Sakellariou, Christina
    Lindstedt, Malin
    Ellmark, Peter
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A511 - A511
  • [7] The novel and potent CD40 agonist KHK2840 augments the antitumor efficacy of anti-PD-1 antibody and paclitaxel
    Kobayashi, Chiaki
    Suzuki-Imaizumi, Minami
    Sakaguchi, Yasuko
    Ishii, Toshihiko
    Adachi, Maiko
    Kaneda, Ayumi
    Ebihara, Ritsuko
    Saito, Masato
    Uemori, Takeshi
    Mori, Kiyotoshi
    CANCER SCIENCE, 2024, 115 (12) : 4008 - 4020
  • [8] Simultaneous Inhibition of PD-1 and Stimulation of CD40 Signaling Pathways by Anti-PD-L1/CD40L Bispecific Fusion Protein Synergistically Activate Target and Effector Cells
    Pandey, Madhu S.
    Wang, Chunlei
    Umlauf, Scott
    Lin, Shihua
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (21)
  • [9] Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity
    Wang, Yan
    Ni, Haiqing
    Zhou, Shuaixiang
    He, Kaijie
    Gao, Yarong
    Wu, Weiwei
    Wu, Min
    Wu, Zhihai
    Qiu, Xuan
    Zhou, Ying
    Chen, Bingliang
    Pan, Donghui
    Huang, Chenrong
    Li, Mingzhu
    Bian, Yicong
    Yang, Min
    Miao, Liyan
    Liu, Junjian
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (02) : 365 - 376
  • [10] Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity
    Yan Wang
    Haiqing Ni
    Shuaixiang Zhou
    Kaijie He
    Yarong Gao
    Weiwei Wu
    Min Wu
    Zhihai Wu
    Xuan Qiu
    Ying Zhou
    Bingliang Chen
    Donghui Pan
    Chenrong Huang
    Mingzhu Li
    Yicong Bian
    Min Yang
    Liyan Miao
    Junjian Liu
    Cancer Immunology, Immunotherapy, 2021, 70 : 365 - 376
12345